CN1269724A - 矿物质通过肠细胞的吸收 - Google Patents
矿物质通过肠细胞的吸收 Download PDFInfo
- Publication number
- CN1269724A CN1269724A CN98806891A CN98806891A CN1269724A CN 1269724 A CN1269724 A CN 1269724A CN 98806891 A CN98806891 A CN 98806891A CN 98806891 A CN98806891 A CN 98806891A CN 1269724 A CN1269724 A CN 1269724A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- mineral
- absorption
- nutritional composition
- enteral nutritional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 40
- 239000011707 mineral Substances 0.000 title claims abstract description 40
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 30
- 230000000968 intestinal effect Effects 0.000 title claims description 16
- 241000186660 Lactobacillus Species 0.000 claims abstract description 56
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 15
- 235000016709 nutrition Nutrition 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 206010061291 Mineral deficiency Diseases 0.000 claims abstract description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 56
- 229910052791 calcium Inorganic materials 0.000 claims description 30
- 239000011575 calcium Substances 0.000 claims description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 29
- 210000001842 enterocyte Anatomy 0.000 claims description 25
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 13
- 235000012054 meals Nutrition 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 102000014171 Milk Proteins Human genes 0.000 claims 1
- 108010011756 Milk Proteins Proteins 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 claims 1
- 235000021239 milk protein Nutrition 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 239000003531 protein hydrolysate Substances 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 239000000047 product Substances 0.000 description 10
- 235000014121 butter Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 238000006384 oligomerization reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 235000012771 pancakes Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 235000015243 ice cream Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000186604 Lactobacillus reuteri Species 0.000 description 4
- 230000002009 allergenic effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000002268 Hexosaminidases Human genes 0.000 description 3
- 108010000540 Hexosaminidases Proteins 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000020244 animal milk Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 235000020167 acidified milk Nutrition 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010001167 Adenocarcinoma of colon Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000005637 Brassica campestris Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000183712 Cerinthe major Species 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000172809 Leuconostoc cremoris Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020189 fortified milk Nutrition 0.000 description 1
- 235000015061 fromage frais Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
Abstract
一种用于增加或便利从膳食中吸收矿物质的方法。给哺乳动物通过肠道施用一种含有乳杆菌的营养组合物。该种营养组合物适用于对受治疗者进行矿物质缺乏症的治疗或防止,或者用于弥补由于膳食中矿物质含量少而造成的生理性缺乏,或者用于满足少年儿童、孕妇、哺乳期妇女及老年人对矿物质的较大的生理需要。
Description
本发明涉及的是一种用于便利或增加哺乳动物从普通膳食中吸收矿物质的方法。具体地，本发明涉及的是一种包括施用一种含有乳杆菌微生物的肠道组合物的方法。
矿物质是主要生理过程的关键元素。例如，钙对骨及牙齿的形成、肌肉的收缩以及激素的合成具有至关重要的作用。钙同时也是大部分细胞激活现象的必不可少的第二信使。
矿物质主要来源于膳食，它穿过肠道粘膜从而进入血流而被身体同化。身体对矿物质的同化(或吸收)程度实际上取决于它们在肠道介质中的溶解性以及肠细胞把它们同化并运输进入血流的能力(R.Wasserman等人，Minerd Absorption in the Monogastric GITrac.Aduances in Experrmental Medicine and Biology，249，45-65，Plenum Press，N.Y.1989)。
许多年来已经对鼠及鸡中钙沿着整个肠道被吸收的位置、效率及机制进行了研究(Bronner F.，J.Nutr.，122，641-643，1992；Schachter D.，Am.J.Physiol.，196，357-362，1959)。由于明显的伦理及技术的原因，对人进行的此类研究是有限的(Hylander E.等人，Scand.J.Gastroenterol.25，705，1990)，而且也仅进行了少数的体外研究(Elsherydan A.等人，Gastroenterology，109，876，1995；Feher J.J.，Am.J.Physiol.，244 C303，1983；Feher J.J.，Cell Calcium，10，189，1989)。
对矿物质吸收研究得最为广泛的一个方面是取决于日常膳食组成情况的矿物质的生物利用度(Bronner F.，J.Nutr.，123 797，1993)。然而，许多生物利用度高的矿物质同时也是不稳定的，而且也不适合被用于膳食中。而且，单纯地往膳食中添加更多数量的矿物质通常对膳食的感官性质会产生消极影响。
这个问题的一个可能的解决方案就是便利或改善矿物质从膳食中的吸收。然而，对便利或改善矿物质从膳食中吸收的方法所进行的研究很少而且结果也不一致。
Rasic等人已经报导说如果乳制品被发酵，其中所含的矿物质将能被更好地同化。这一效果归因于经过发酵的乳制品中存在酸(XP002052238；Fermented Fresh Milk Product，第一卷，第114-115页，1978)。
最近，Yaeshima等人也示明当给小鼠提供钙强化乳清膳食并同时喂食寡聚糖及双岐杆菌时，钙的吸收得以增加(XP002052237：Bukketinof the International Dairy Fermentation，No.313，1996)。
然而，Kot等人则报导说嗜酸乳杆菌正常情况下使Fe2+内在化并把其氧化为Fe3+，Fe3+是一种不溶性形式并且更难以被同化(J.Agric.Food Chem.，43，1276-1282，1995)。
因此，需要获得一种便利或增加膳食中矿物质吸收的方法。
相应地，本发明提供了一种用以增加从膳食中吸收矿物质的方法。该方法包括通过肠道给哺乳动物施用一种含有乳杆菌的营养组合物。
我们惊奇地发现，通过使用一个体外模型，乳杆菌可以直接便利或改善人肠细胞对矿物质，特别是钙的吸收。我们不受理论束缚地认为这是与肠细胞及与其接触的细菌周围的微环境所诱发的酸化有关联的。细菌和肠细胞都可能参与了酸化的诱发。因此，这一局部的酸化作用可能对矿物质的溶解从而以及身体对它们的同化能力具有积极的作用。
另一方面，本发明还提供了把乳杆菌用于制备一种用于便利或改善哺乳动物对矿物质吸收的肠道营养组合物的用法。这种肠道营养组合物可被用于治疗或预防矿物质缺乏症。
现在以示例的形式参照附图来描述本发明的实施例，其中：
图1代表在没有乳杆菌存在时，肠细胞Caco-2对钙的基本吸收；
图2代表大约6.7×107 cfu/ml的各种不同的乳杆菌菌株对肠细胞Caco-2对钙的吸收的影响；
图3代表大约3.4×108 cfu/ml的各种不同的乳杆菌菌株对肠细胞Caco-2对钙的吸收的影响；
本发明涉及通过肠道施用一种营养组合物，此种组合物含有乳杆菌以便利或改善对日常膳食中的矿物质的吸收。矿物质的例子有钙、锰、铁及/或锌。乳杆菌的摄取增加了矿物质的生物利用度，也就是说这使得通常在肠中并不很好溶解的矿物质变得更易于被肠细胞吸收。
可以使用任何食品级的乳杆菌菌株。例如可以使用下列的乳杆菌：嗜酸乳杆菌(Lactobacillus acidophilus)，卷曲乳杆菌(LactobacillusCrispatus)，Lactobacillus amylovorous，鸡乳杆菌(Lactobacillusgallinarum)，加氏乳杆菌(Lactobacillus gasseri)以及Lactobacillusjohnsonii；Lactobacillus paracasei；路氏乳杆菌(Lactobacillusreuterii)；Lactobacillus brevis；Lactobacillus fermentum；Lactobacillus plantarum；Lactobacillus casei特别是L.casei subsp.casei以及L.casei subsp.rhamnosus；Lactobacillus delbruckii特别是L.delbruckii subsp.lactis、L.delbruckii subsp.helveticus以及L.delbruckii subsp.bulgaricus；以及Leuconstoc mesenteroides特别是例如L.mesenteroides subsp.cremoris(Bergey′s Manualof Syslemntio Bacteriology，第二卷，1986；Fujisawa等人，Int.Syst.Bact.42，487-491，1992)。
乳杆菌可以是能够粘附到肠细胞上的，但这并非是必须的。然而，优选的乳杆菌应是那些在体外每100个肠细胞可以粘附到50个，特别地至少80个的细菌。为了挑选出这样一种粘附型的细菌，可以在一肠上皮细胞永生系的汇合培养物上涂布细菌培养物进行培养(EP0802257)，然后把汇合培养物进行清洗并计数粘附到细胞系被长绒毛上的细菌数目。
益生型(probiotic)的乳杆菌是特别令人感兴趣的。有一些菌株实际上能够粘附到人的肠细胞上、能够把位于人肠细胞上的病原性细菌排除，以及/或者能够通过允许人的免疫***对外来侵袭产生更强的反应来对人的免疫***产生作用(即具有免疫调控能力)，例如通过增强来源于人血的粒性白细胞的噬菌作用来实现(J.of Dairy Science，78，491-497，1995；具有免疫调控能力的La-1菌株于1992年6月30日被Nestec SA根据Budapest条约存放于Conection Nationale deCulture de Microorganisme(CNCM)，25 rue docteur Roux，75724 Paris，于此它的存放号码被标志为CNCM I-1225)。这一菌株被描述于EP 0577904中。
作为示例，可以使用益生型菌株Lactobaciuas acidophilus(嗜酸乳杆菌)CNCM I-1225。这一菌株最近被根据Fujisawa等人提出的新分类法重新分类到Lactobacillus johnsonii细菌中，上述这一新的分类法现在是嗜酸乳杆菌分类学领域的权威性分类法(Int.J.Syst.Bact.42，487-791，1992)。还有其他的益生菌可供使用，如在EP0199535(Gorbach等人)、US 5296221(Mitsuoka等人)、US 556785(Institut Pasteur)或US 5591428(Probi AB)中所描述的那一些。
营养组合物优选地包含有足量的活乳杆菌以便利矿物质被肠细胞吸收，例如至少为106 cfu/ml，特别的为107-1011 cfu/ml，优选的为108-1011 cfu/ml(“cfu”表示“菌落形成单位”)。
营养组合物也可以同时根据需要包含有其它的细菌：如其它的益生菌。
营养组合物也可以同时包含有合适的蛋白质来源；如动物或植物蛋白来源。合适的蛋白来源有乳蛋白、大豆蛋白、大米蛋白、小麦蛋白、高梁蛋白等等。这些蛋白质可以是未经过处理的，也可以是经过水解的。
营养组合物也可以同时包含有合适的碳水化合物来源；例如蔗糖、果糖、葡萄糖、麦芽糖糊精等等。
营养组合物也可以同时包含有合适的类脂来源；例如一种合适的动物或植物类脂来源。合适的类脂来源包括乳脂肪、向日葵油、油菜籽油、橄榄油、红花油等等。
营养组合物也可以同时强化有矿物质或维生素。特别优选的是用钙对营养组合物进行强化。
营养组合物可被制备成食品组合物形式以便供人或动物食用。合适的食品组合物可以被制备成液体、粉末以及固体形式。
营养组合物可以经过发酵以获得足量的乳杆菌。因此基于乳的经过发酵的组合物是特别合适的。术语“乳”不仅指动物乳，还指通常被称为蔬菜乳的物质，好即一种经过处理或未经过处理的植物材料，如，豆类(大豆、鹰嘴豆、扁豆等)或含油种子(油菜、大豆、芝麻、棉花等等)的提取物，这些提取物含有溶解的或呈胶状悬浮的蛋白质，它们可以通过化学反应、酸发酵及/或加热而凝固。与动物乳类似，可以把这些蔬菜乳进行热处理。也可以对它们进行专门的处理，如进行脱色，除臭或通过处理消除其不受欢迎的味道。最后，这一术语也可以代表动物乳及植物乳的混合物。
可以在制备的过程中给营养组合物添加、混合或涂覆适当量的乳杆菌培养物，这一培养物根据需要可以呈液体、浓缩、干燥或胶囊化等形式。
业已发现乳杆菌的微型胶囊化对治疗是有利的。首先，微型胶囊化显著地增加了乳杆菌的存活从而增加了到达肠道的活乳杆菌的数目。更为重要的是，乳杆菌是被逐步释放进入肠道的，这使乳杆菌对矿物质经由肠细胞的吸收所产生的作用得以延长。
优选地，当要把乳杆菌进行微型胶囊化时，先把乳杆菌冻干或喷干(EP 0818529)，然后把它们掺合到含有，例如，固化脂肪酸、海藻酸盐、聚合的羟丙基甲基纤维素或聚合的多聚乙烯吡咯烷酮的凝胶中。为了实际这一点，FR 2,443,247中的教导被作为参照结合于本文中。
营养组合物并不必含有乳杆菌在肠道介质中进行主动发酵所需的碳水化合物。相反地，被易化的矿物质的吸收并不依赖于乳杆菌的发酵活动，而是乳杆菌与肠细胞直接接触的结果。这被认为诱导了微环境的酸化从而使矿物质的溶解度得到改善。
然而，为乳杆菌在肠道介质中进行更新或进行特异性增殖提供条件从而延长矿物质吸收的易化作用是合乎需要的。这可以通过在营养组合物中添加纤维来实现，这些纤维便利了乳杆菌在肠道介质中的特异性增殖。这些纤维是可溶性的而且是可以被发酵的。
这些纤维可以选自，例如：植物果胶、寡聚壳糖、寡聚果糖、寡聚龙胆糖、寡聚半乳糖、寡聚异麦芽糖、寡聚甘露糖或寡聚木糖或者例如来源于大豆的寡聚糖(Playne等人。Bulletin of the IDF 313，Group B42，Annuol Session of September 95，Vienna)。
优选的果胶有分子量为10至400 KDa之间的α-1，4-D-半乳糖醛酸多聚物，它可以被提取自，例如，胡萝卜或西红柿(JP 60104432)。优选的寡聚半乳糖包含一个含有2至5个〔-α-D-Glu-(1→4)-β-D-Gal-(1→6)-〕结构重复单元的糖部分(Yakult HonsaCo.，Japan)。优选的寡聚果糖是从菊苣中提取的菊淀粉-寡聚果糖，它可以包含有，例如，1至9个〔-β-D-Fru-(1→2)-β-D-Fru-(1→2)-〕结构重复单元(WO 94/12541；RaffinerieTirlemontoise S.A.，Belgium)或者由蔗糖单元合成的寡聚糖，它可以包含有，例如，一个包括2至9个〔-α-D-Glu-(1→2)-β-D-Fru-(1→2)-〕结构重复单元的糖部分(Meiji Seika KasihaCo.，Japan)。优选的寡聚麦芽糖包含有一个由2至7个〔-α-D-Glu-(1→4)-〕结构重复单元组成的糖部分(Nihon Shokuhin KakoCo.，Japan)。优选的异麦芽糖包括一个由2至6个〔-α-D-Glu-(1→6)-〕结构重复单元组成的糖部分(Showa Sangyo Co.，Japan)。优选的寡聚壳糖包括一个由2至5个〔-β-D-Glu-(1→6)-〕结构重复单元组成的糖部分(Nihon Shokuhin Kako Co.，Japan)。最后，优选的寡聚木糖包括，例如，一个由2至9个〔-β-xyl-(1→4)-〕结构重复单元组成的糖部分(Suntory Co.，Japan)。
营养组合物中纤维的数量取决于它们促进乳杆菌发育的能力。通常营养组合物可以含有1-50％的此类纤维(相对于干物质的比重)。乳杆菌的浓度至少为每克纤维103 CFU，优选的为每克纤维104-107CFU。
纤维所提供的另一个优点是它可以阻滞肠的运输。如果纤维的数量多，如有组合物重量的20-50％，情况更是如此。乳杆菌被肠的运输作用逐渐除去，这样就可以延长乳杆菌对矿物质经由肠道的吸收所产生的有益作用。
营养组合物可以采取任何经由肠道施用的食品的形式，例如，营养组合物可以采取经过发酵的乳的形式(EP 0577904)、婴儿食品的形式(EP 0827697)、清爽干酪的形式(PCT/EP97/06947)、成熟干酪的形式、冰激凌的形式(WO 98/09535)、填充有奶油的饼干的形式(EP 704164；EP 66031)、干的香肠及/或馅饼的形式(EP 689769)。
营养组合物也可以采取适合于不能忍受乳制品的人们的形式。这些营养组合物不含有可引起过敏症的乳衍生物。例如，可以给对乳蛋白过敏的儿童配制一种含有不足以引起过敏症的乳衍生物的营养组合物。这些乳衍生物可以是附合欧洲指令96/4/EC的，这一指令声明不足以引起过敏症的乳中所含的可引起过敏症的蛋白通过免疫监测至少应比未经水解的乳中的少100倍(off J.Europ.Comm.，NOL49/12，annex point 5.a.1996；Fritsche等人，Int.Arch.Aller.andAppl.Imm.93，289-293，1990)。
营养组合物特别适合于对患有矿物质缺乏症的人进行治疗或预防，或者用于弥补因为膳食中矿物质含量少而引起的生理性缺乏，或者用于满足少年儿童、孕妇、哺乳期妇女及老年人对矿物质的较大的生理需求。
现在通过具体的例子对本发明进一步进行描述。百分比除了特别标示的以外，都表示重量百分比。这些例子仅是解释性的，并不对本发明构成任何意义上的局限。例1-材料：45CaCl2，Amersham产品，荧光黄，Sigmao产品胶原质I，Centrix Pharmaceuticals产品，PBS，HEPES及细胞培养基的组分，Gibco产品，培养载体，Falcon产品。-细胞培养：人Caco-2细胞系，提取自结肠腺癌，来自AmericanType Culture Collection(第41代)。把细胞放置于含有4.5g/l葡萄糖、20％热灭活胎牛血清、1mg/ml两性霉素B、100U/ml青霉素/链霉素、200ug/ml庆大霉素及1％非必需氧基酸的DMEM中培养，数量为4×104个细胞/cm2。定期用胰酶对细胞进行消化，然后再把其1∶20重新培养。用于运输实验的细胞是在一预先涂覆有一层50ug/ml的胶原质I的可通透内眼板上进行培养的，数量为1×105个细胞/cm2。在所有的情况中细胞都被保持在37℃的10％CO2/90％空气的培养箱中，而且培养基都是每两天换一次。-CaCo-2细胞的生存力：为了排除在有乳杆菌存在时钙经由肠细胞的吸收的增强是由细胞的损坏造成的这样一种可能性，取用每一样品的一部分用于对钙进行化验，把其用于氨基己糖苷酶活性化验(Landegren等人，J.Immunol.Method，67，379-378，1984)。这一比色测验可以通过测量从损坏细胞的胞质液释放进入上清的氨基己糖苷酶的活性来对细胞裂解及/或死亡进行定量。结果表明在所有的实验中，当有乳杆菌存在时，氨基己糖苷酶的活性是相当的。-细胞层的通透性：Caco-2细胞生长终了时所形成的细胞层的完整性及其分化是通过用一伏特表/欧姆表Millicell-ERS对跨上皮电阻(transepithelial electrical resistance，TEER)进行测量而得以评估的。当这一电阻达到700欧姆x cm2时即进行钙吸收实验。在钙吸收实验过程中细胞层的通透性是通过对荧光黄(一种不跨越细胞膜的分子)的扩散水平(％)进行测量而得以评估的。-钙的运输：把Caco-2细胞在内眼板上培养3至5周。实验当天把细胞层在PBS中清洗2次，然后往加入浆膜的内眼板的底腔(细胞基底横向极)中加入2.5ml添加有2.5mM Cacl2的载体缓冲液(140mMNaCl，5.8mM KCl，0.34mM NaH2PO4，0.44mM KH2PO4，0.8mMMgSO4，20mM HEPES，4mM谷氨酸盐，25mM葡萄糖，pH 7.4)，往结合肠腔的内眼板的顶腔(细胞的顶极)中加入1.5ml的添加有10mMCaCl2及痕量的45CaCl2及荧光黄的载体缓冲液。把内眼板放置于37℃并定期从底腔及顶腔取出50μl的样品。
用液体闪烁计数法来评估这些样品中所含的放射性，这样就可以推断常温下被吸收的钙的数量。钙的基本运输量被表达为被运输到内眼板底腔的钙的n mol数。通过分光荧光测定法监测到的荧光黄在底腔的扩散量被表达为被引入到顶腔中的数量的百分比(％)。-乳杆菌的影响：在厌氧条件下对菌株Lactobacillus johnsonii La1(CNCM I-1225)、La17、La22、La31；Lactobacillus acidophilusLa10、La18、La31；Lactobacillus bulgaricus Lfi5、YL8；Lactobacillusparacasei ST11；Lactobacillus gasseri LGA7；Lactobacillus reuteriLR7及Streptococcus thermophilus Sfi20、YS4(Nestec Collection，Lausanne，Switzerland)进行培养，Lactobacillus用MRS肉汤培养，Streptococcus用M17培养，时间为两个24小时，用PBS清洗并用载体缓冲液重悬，然后再把其引入内眼板的顶腔。根据试验此时的Caco-2；细菌的比率大约为1∶100(在图2及3所代表的实验中，内眼板顶腔的数量为6.7×107或3.4×108 cfu/ml)。根据上述的方案对钙的吸收进行评估。-钙基本运输的结果：通过往底腔中加入2.5mM的CaCl2来在内眼板中建立一个钙梯度，这是与人血浆中正常的浓度相对应的，同时任意地往顶腔中加入10mM的CaCl2，这对应于食物中钙的含量。如图1中所图解的一个代表性实验的结果所示，钙经由Caco-2细胞的基本吸收量随时间增加并在4小时后达到600 n mol/内眼板，每个内眼板含有3×106个细胞。作为对实验期间细胞层完整性的一个检验，对荧光黄的扩散量进行了测量并证明其扩散量少于2％。-乳杆菌影响的测量：在图2及3中，当有粘附性的Lactobacillusjohnsonii菌株La1及La22存在时、当有非粘附性的La10及La18Lactobacillus acidophilus菌株存在时、以及当有L.paracasei(ST11)，L.gssseri(LGA7)及L.reuterii(LR7)菌株存在时，Caco-2细胞对钙的吸收显著增加。
因此，细菌粘附到肠细胞上的能力并不与它们增加这些细胞的钙吸收能力有直接的关联。在所有的实验中，都用类似的方法对荧光黄的扩散进行了调控，但其扩散量是可以忽略不计的。
当Caco-2细胞与乳杆菌(除Sfi20菌株之外的任何菌株)同时存在时，可以观察到内眼板顶腔的pH值降低(表格1)。因此，钙吸收的增加与这一pH值的降低并不存在关联。然而，某些能够增加钙吸收的特定的细菌菌株在没有Caco-2细胞存在的时候并无法将实验性的培养基酸化。这意味着在有Caco-2细胞存在时细菌的酸化作用需要这两种有机物之间的相互协作并且可能归因于Caco-2细胞。表格1：在没有Caco-2细胞存在时乳杆菌对实验性培养基pH的影响
例2
| 细菌 | 试验次数 | 无Caco-2时的pH | 有Caco-2时的pH |
| 无 | 4 | 7+/-0 | 7+/-0 |
| La1 | 3 | 6.75+/-0.3 | 3.75+/-0.3 |
| La10 | 3 | 4.65+/-0.3 | 4.15+/-0.3 |
| La17 | 2 | 7+/-0 | 3.5+/-0.7 |
| La18 | 2 | 7+/-0 | 3.5+/-0.5 |
| La22 | 2 | 7+/-0 | 3.25+/-0.35 |
| La29 | 2 | 4.25+/-0.35 | 3.5+/-0 |
| La31 | 2 | 7+/-0 | 3.75+/-0.35 |
| Sfi20 | 1 | 7 | 7 |
| YS4 | 1 | 5 | 4 |
| Lfi5 | 1 | 4 | 3 |
| YL8 | 1 | 4 | 3 |
进行类似于例1中的试验以确定当有经过标记的菊淀粉(3H-菊淀粉，Amershcm，示踪生物前纤维)存在时，乳杆菌对钙经由肠细胞吸收的影响。结果证实了乳杆菌在体外增加了矿物质经由肠细胞的吸收。例3
进行类似于例1中的试验以确定乳杆菌对锰、铁及锌经由肠细胞吸收的影响。结果证实了乳杆菌在体外增加了矿物质由肠细胞的吸收。例4 乳酸细菌的胶囊化
在一个100升的槽中制备80升含有以下组分(％)的培养基：
| 酵母提取物 | 0.25％ |
| Typticase | 1.00％ |
| Phytone | 0.50％ |
| 葡萄糖 | 1.50％ |
| L-半胱氨酸HCl | 0.05％ |
| K2HPO4 | 0.25％ |
| ZnSO4 | 0.025％ |
| FeCl3 | 痕量 |
| 水 | 补充到100 |
用1升经过20小时培养的Lactobacillus johnsonii La1(CNCMI-1225)培养物进行接种。把培养基在30℃温育12小时。把肉汤培养物离心获得240g细胞。把它们稀释在250ml添加有7％乳糖的脱脂乳中。用液氮把混合物冷冻。在40℃冻干过夜。用一种溶点为42℃并在45℃液化的氢化蔬菜脂肪把所获得的粉末制备成5％的分散体。在一个直径1.5米高10米的垂直圆筒的顶部把分散体在45℃用千微巴(bar)的压力与液氮按1∶5的份额进行注射。把一容器放置于圆筒的底部并于其中盛上液氮，让含有细菌的直径介于0.1至0.5mm之间的微珠收集于液氮中。接着把微珠放置于一液化的填充物(bed)中，把一含有8％玉米蛋白的乙醇溶液喷洒于填充物上，其数量应使得包绕着微珠而形成的玉米蛋白层占两者总重量的5％。
接着把这些微珠掺合到食品组合物中以便利矿物质被肠细胞吸收。例5
把大约11％的乳脂肪、8.8％的乳固体(无脂肪固体)、25％蔗糖、5％葡萄糖浆及0.6％的Emulstab SE30在60-65℃混合20分钟以制备浓缩的冰激凌主料。把主料在72-75℃，210微巴(bar)下进行匀浆(分210/50微巴两个阶段进行)，然后把其在85℃进行22秒的巴氏法灭菌(APV巴氏法灭菌器，France，Evreux，400升/小时)，把其冷却到4℃，往其中加入40％的用Lactobacillus johnsonii La-1(5×108 cfu/ml)和Bifidobacterium longum Bi16(3×108 cfu/ml)酸化的乳。下表给出了浓缩后的主料的组成：
| 成分 | 组成(kg) | 脂肪(％) | 无脂肪固体(％) | 蔗糖(％) | 干的提取物(％) |
| 奶油(35％) | 31.43 | 11.00 | 1.57 | 12.57 | |
| 脱脂奶粉 | 7.60 | 7.30 | 7.30 | ||
| 蔗糖 | 36.77 | 25.00 | 25.00 | ||
| 葡萄糖浆 | 5.27 | 5.00 | |||
| EmulstabSE30 | 0.67 | 0.63 | |||
| 水 | 18.26 | ||||
| 总计：奶油主料 | 100.00 | 11.00 | 8.87 | 25.00 | 50.50 |
| 奶油主料(60％) | 60.00 | 6.60 | 5.32 | 15.00 | 30.30 |
| 酸化乳(40％) | 40.00 | 1.40 | 4.68 | - | 6.08 |
| 总计：奶油主料+酸化乳 | 100.00 | 8.00 | 10.00 | 15.00 | 36.38 |
当奶油在5℃下熟化12小时之后，把它冷冻使其体积膨胀95％(Crepaco速冻机，France，Evreuk；160升产品/小时)。
根据下面的配方制备一含有10％寡聚果糖RaftiloseL30(Raffinerie Tirlemontoise S.A.，BE)的薄饼生面团。经过烘烤之后，把薄饼做成通常的锥形。经过冷却之后，在锥形薄饼的内侧喷涂一薄层的脂肪然后往薄饼中填入经过如上搅拌的冰激淋。每一个11.5g的锥形薄饼使用130ml经过搅拌的冰激淋(大约65g)及5g的巧克力(喷洒于奶油之上)。
| 成分 | 重量(g) | 供应商 |
| 普通小麦粉55淀粉寡聚果糖RaftiloseL30蔗糖脂肪乳化剂盐总计：薄饼配方 | 520.21027.881.50.5 | RaffinerieTirlemontoiseS.A.，BE |
| 100 |
这样，每个冰激淋锥形薄饼可以提供1.1g的纤维和大约108cfu/g的乳杆菌，这些纤维通过促进乳杆菌在肠道中的特异性发育而促进了矿物质的同化作用。
Claims (10)
1.乳杆菌在制备肠道营养组合物以便利或改善哺乳动物对矿物质的吸收中的应用。
2.如权利要求1中所述的应用，其中的乳杆菌是能够粘附到肠细胞上的乳杆菌。
3.如权利要求2中所述的应用，其中的乳杆菌是Lactobacillusjohnsonii CNCM I-1225菌株。
4.如权利要求1中所述的应用，其中的肠道营养组合物含有107至1011 cfu的乳杆菌。
5.如权利要求1中所述的应用，其中的肠道营养组合物可以便利钙、锰、铁及/或锌的吸收。
6.如权利要求1中所述的应用，其中的肠道营养组合物含有乳蛋白。
7.如权利要求6中所述的应用，其中的肠道营养组合物是一种由不足以引起过敏反应的乳蛋白水解物组成的婴儿配方。
8.如权利要求1中所述的应用，其中的肠道营养组合物进而包含益生型纤维。
9.乳杆菌在制备肠道营养组合物以对矿物质缺乏症进行治疗或预防中的应用。
10.一种用以增加从膳食中吸收矿物质的方法，该方法包括给哺乳动物通过肠道施用一种含有乳杆菌的营养组合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97111380.8 | 1997-07-05 | ||
| EP97111380 | 1997-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1269724A true CN1269724A (zh) | 2000-10-11 |
Family
ID=8227023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98806891A Pending CN1269724A (zh) | 1997-07-05 | 1998-06-26 | 矿物质通过肠细胞的吸收 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20020127211A1 (zh) |
| EP (1) | EP1003532B2 (zh) |
| JP (1) | JP2002507997A (zh) |
| KR (1) | KR20010015563A (zh) |
| CN (1) | CN1269724A (zh) |
| AR (1) | AR013175A1 (zh) |
| AT (1) | ATE208205T1 (zh) |
| AU (1) | AU743914B2 (zh) |
| BR (1) | BR9810547B1 (zh) |
| CA (1) | CA2294099C (zh) |
| CZ (1) | CZ300387B6 (zh) |
| DE (1) | DE69802413T3 (zh) |
| DK (1) | DK1003532T4 (zh) |
| ES (1) | ES2168785T5 (zh) |
| HK (1) | HK1029737A1 (zh) |
| HU (1) | HUP0003995A3 (zh) |
| IL (1) | IL133412A (zh) |
| MY (1) | MY122501A (zh) |
| NO (1) | NO322188B1 (zh) |
| NZ (1) | NZ501933A (zh) |
| PL (1) | PL337967A1 (zh) |
| PT (1) | PT1003532E (zh) |
| RU (1) | RU2214258C2 (zh) |
| TR (1) | TR200000021T2 (zh) |
| WO (1) | WO1999002170A1 (zh) |
| ZA (1) | ZA985893B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102227223B (zh) * | 2008-11-28 | 2013-03-20 | 株式会社明治 | 矿物质吸收改善剂和矿物质吸收改善方法 |
| CN104207135A (zh) * | 2005-07-05 | 2014-12-17 | 普罗比公司 | 乳杆菌用于增加选自铁、锌、钙的金属及其离子的吸收的用途 |
| CN104363769A (zh) * | 2012-02-28 | 2015-02-18 | 康奈尔大学 | 益生菌组合物和方法 |
| CN108030096A (zh) * | 2017-12-18 | 2018-05-15 | 浙江民生健康科技有限公司 | 一种钙铁锌与益生菌组合物及其应用 |
| CN115884688A (zh) * | 2020-05-25 | 2023-03-31 | 热尔韦·达诺尼公司 | 用于预防或治疗矿物质缺乏的乳酸乳球菌 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197356B1 (en) * | 1993-08-03 | 2001-03-06 | Immunopath Profile, Inc. | Process for preparing hypoallergenic foods |
| ATE208205T1 (de) * | 1997-07-05 | 2001-11-15 | Nestle Sa | Lactobacilli zur erhöhung der mineralienabsorption durch darmzellen |
| DE10008279A1 (de) * | 2000-02-23 | 2001-08-30 | Meggle Gmbh | Milchzucker enthaltende Zusammensetzung |
| JP3363438B2 (ja) | 2000-05-02 | 2003-01-08 | ビオフェルミン製薬株式会社 | 噴霧乾燥による菌体乾燥物 |
| GB0027761D0 (en) * | 2000-11-14 | 2000-12-27 | Nestle Sa | Nutritional composition for an immune condition |
| KR100419132B1 (ko) * | 2000-12-29 | 2004-02-18 | 조성근 | 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01 |
| DE10213280A1 (de) * | 2002-03-25 | 2003-10-23 | Mars Inc | Proteinhaltiges Nahrungsmittelerzeugnis und Verfahren zu seiner Herstellung |
| EP1477173B1 (en) * | 2003-05-16 | 2007-12-19 | Kao Corporation | Use of monosaccharide posphates for improving the intestinal function |
| JP4485169B2 (ja) * | 2003-05-16 | 2010-06-16 | 花王株式会社 | 腸管ミネラル吸収能改善剤 |
| JP4782385B2 (ja) * | 2003-05-29 | 2011-09-28 | 昭和産業株式会社 | 免疫賦活剤 |
| ES2416287T3 (es) * | 2003-06-23 | 2013-07-31 | Nestec S.A. | Empleo de una fórmula nutritiva para la función óptima de la barrera intestinal |
| JP4553604B2 (ja) * | 2003-06-30 | 2010-09-29 | 明治製菓株式会社 | 一般食品、保健機能食品または健康補助食品の機能増強組成物及びその方法 |
| US6936598B2 (en) * | 2003-11-21 | 2005-08-30 | Hill's Pet Nutrition, Inc. | Composition and method |
| US7754677B2 (en) * | 2003-12-05 | 2010-07-13 | Hill's Pet Nutrition, Inc. | Composition and method for reducing diarrhea in a mammal |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| WO2006012739A1 (en) * | 2004-08-02 | 2006-02-09 | UNIVERSITé LAVAL | Nutritional ingredient containing bioavailable mineral nutrients |
| US20060194241A1 (en) * | 2005-02-28 | 2006-08-31 | Jan Knol | Lactobacillus specific probes |
| AU2006253006B8 (en) | 2005-05-31 | 2011-09-15 | Alimentary Health Ltd | Feline probiotic Lactobacilli |
| AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
| US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
| US8075934B2 (en) * | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
| US8287931B2 (en) * | 2005-06-30 | 2012-10-16 | Mead Johnson Nutrition Company | Nutritional composition to promote healthy development and growth |
| DK1992351T3 (en) * | 2007-05-18 | 2016-06-06 | Nestec Sa | Lactobacillus johnsonii for the prevention of post-surgical infection |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US8986769B2 (en) * | 2008-10-24 | 2015-03-24 | Mead Johnson Nutrition Company | Methods for preserving endogenous TGF-β |
| US8425955B2 (en) * | 2009-02-12 | 2013-04-23 | Mead Johnson Nutrition Company | Nutritional composition with prebiotic component |
| US8293264B2 (en) * | 2009-05-11 | 2012-10-23 | Mead Johnson Nutrition Company | Nutritional composition to promote healthy development and growth |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| US20110070334A1 (en) | 2009-09-20 | 2011-03-24 | Nagendra Rangavajla | Probiotic Stabilization |
| JP2014516589A (ja) | 2011-06-20 | 2014-07-17 | エイチ．ジェイ．ハインツ カンパニー | プロバイオティック組成物及び方法（ｐｒｏｂｉｏｔｉｃｃｏｍｐｏｓｉｔｉｏｎａｎｄｍｅｔｈｏｄｓ） |
| CA2908051C (en) * | 2013-04-03 | 2021-03-02 | Probi Ab | Probiotic strains for use in treatment or prevention of osteoporosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2536996B1 (fr) * | 1982-12-01 | 1985-09-27 | Grimberg Georges | Association permettant d'ameliorer l'absorption de divers cations par l'organisme |
| JPH0678367B2 (ja) * | 1990-05-15 | 1994-10-05 | 呉羽化学工業株式会社 | 食物繊維、その製造法及びその食物繊維を含有する生理活性剤 |
| DK0768375T4 (da) * | 1992-07-06 | 2002-09-16 | Nestle Sa | Mælkesyrebakterier |
| JP3618774B2 (ja) * | 1993-08-10 | 2005-02-09 | 雪印乳業株式会社 | 鉄欠乏性貧血治療用組成物 |
| JPH10158178A (ja) * | 1996-11-29 | 1998-06-16 | Yakult Honsha Co Ltd | ミネラル吸収促進剤およびミネラル強化剤 |
| ATE208205T1 (de) * | 1997-07-05 | 2001-11-15 | Nestle Sa | Lactobacilli zur erhöhung der mineralienabsorption durch darmzellen |
-
1998
- 1998-06-26 AT AT98939584T patent/ATE208205T1/de not_active IP Right Cessation
- 1998-06-26 AU AU88045/98A patent/AU743914B2/en not_active Expired
- 1998-06-26 WO PCT/EP1998/004036 patent/WO1999002170A1/en not_active Application Discontinuation
- 1998-06-26 US US09/445,796 patent/US20020127211A1/en not_active Abandoned
- 1998-06-26 JP JP50808499A patent/JP2002507997A/ja active Pending
- 1998-06-26 TR TR2000/00021T patent/TR200000021T2/xx unknown
- 1998-06-26 KR KR1020007000073A patent/KR20010015563A/ko not_active Application Discontinuation
- 1998-06-26 CA CA002294099A patent/CA2294099C/en not_active Expired - Fee Related
- 1998-06-26 HU HU0003995A patent/HUP0003995A3/hu unknown
- 1998-06-26 CZ CZ20000023A patent/CZ300387B6/cs not_active IP Right Cessation
- 1998-06-26 PL PL98337967A patent/PL337967A1/xx not_active Application Discontinuation
- 1998-06-26 NZ NZ501933A patent/NZ501933A/en unknown
- 1998-06-26 BR BRPI9810547-7A patent/BR9810547B1/pt not_active IP Right Cessation
- 1998-06-26 CN CN98806891A patent/CN1269724A/zh active Pending
- 1998-06-26 RU RU2000102713/14A patent/RU2214258C2/ru active
- 1998-06-26 DK DK98939584T patent/DK1003532T4/da active
- 1998-06-26 EP EP98939584A patent/EP1003532B2/en not_active Expired - Lifetime
- 1998-06-26 DE DE69802413T patent/DE69802413T3/de not_active Expired - Lifetime
- 1998-06-26 ES ES98939584T patent/ES2168785T5/es not_active Expired - Lifetime
- 1998-06-26 PT PT98939584T patent/PT1003532E/pt unknown
- 1998-06-26 IL IL13341298A patent/IL133412A/xx not_active IP Right Cessation
- 1998-07-03 MY MYPI98003035A patent/MY122501A/en unknown
- 1998-07-03 AR ARP980103248A patent/AR013175A1/es not_active Application Discontinuation
- 1998-07-03 ZA ZA9805893A patent/ZA985893B/xx unknown
-
1999
- 1999-12-15 NO NO19996214A patent/NO322188B1/no unknown
-
2000
- 2000-11-21 HK HK00107440A patent/HK1029737A1/xx not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104207135A (zh) * | 2005-07-05 | 2014-12-17 | 普罗比公司 | 乳杆菌用于增加选自铁、锌、钙的金属及其离子的吸收的用途 |
| CN102227223B (zh) * | 2008-11-28 | 2013-03-20 | 株式会社明治 | 矿物质吸收改善剂和矿物质吸收改善方法 |
| CN104363769A (zh) * | 2012-02-28 | 2015-02-18 | 康奈尔大学 | 益生菌组合物和方法 |
| US9700586B2 (en) | 2012-02-28 | 2017-07-11 | Cornell University | Probiotic compositions and methods |
| CN108030096A (zh) * | 2017-12-18 | 2018-05-15 | 浙江民生健康科技有限公司 | 一种钙铁锌与益生菌组合物及其应用 |
| CN115884688A (zh) * | 2020-05-25 | 2023-03-31 | 热尔韦·达诺尼公司 | 用于预防或治疗矿物质缺乏的乳酸乳球菌 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1269724A (zh) | 矿物质通过肠细胞的吸收 | |
| Ranadheera et al. | Importance of food in probiotic efficacy | |
| US6835376B1 (en) | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria | |
| RU2259747C2 (ru) | Штамм bifidobacterium, способ получения иммуностимулирующего молочного продукта и продукт, полученный этим способом | |
| WO2007085970A2 (en) | Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders | |
| TWI739495B (zh) | 可促進排便的組合物及其用途 | |
| EP3443969A1 (en) | Brain function-improving composition for newborns | |
| RU2451067C2 (ru) | Способ повышения жизнеспособности бифидобактерий в процессе хранения свежего ферментированного пищевого продукта | |
| CN109715181B (zh) | 细菌 | |
| CN109715784A (zh) | 细菌 | |
| CN102300472A (zh) | 共生组合物及其制备方法 | |
| RU2261909C1 (ru) | КОНСОРЦИУМ БИФИДОБАКТЕРИЙ Bifidobacterium bifidum 791-МБ, Bifidobacterium longum В 379М-МБ, Bifidobacterium adolescentis Г-7513- МБ, Bifidobacterium infantis 73-15-МБ, Bifidobacterium breve 79-119-МБ, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПРИГОТОВЛЕНИЯ КИСЛО-МОЛОЧНЫХ, НЕФЕРМЕНТИРОВАННЫХ ПРОДУКТОВ, БИОЛОГИЧЕСКИ АКТИВНЫХ ДОБАВОК, БИФИДОСОДЕРЖАЩИХ ПРЕПАРАТОВ, КОСМЕТИЧЕСКИХ И ГИГИЕНИЧЕСКИХ СРЕДСТВ | |
| US20230149482A1 (en) | Composition for improving gut microbiota | |
| JP2021164435A (ja) | ビフィズス菌増殖促進剤 | |
| MXPA99012017A (en) | Absorption of minerals by intestinal cells | |
| Shсhyokotova et al. | STUDY OF BIOLOGICAL RELATIONSHIPS AND BIOCHEMICAL PROPERTIES OF PROBIOTIC MICROORGANISMS | |
| DK200500255U3 (da) | Probiotisk, bredspektret ernæringspræparat i pulver-, væske-, pasta- eller gasform | |
| RU2180914C1 (ru) | Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактериальных препаратов, заквасок для кисломолочных продуктов, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, предназначенных для коррекции микрофлоры человека в возрасте от 12 лет и старше | |
| Gawai et al. | Formulation, Sensory and Microbial Aspects of Functional Fermented Dairy Product-Synbiotic Dahi | |
| RU2290436C2 (ru) | Штамм bifidobacterium lactis 676, используемый для приготовления кисломолочных лечебно-профилактических продуктов, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, пробиотика и косметических средств | |
| CN115968941A (zh) | 一种益生菌羊奶片及其制备方法 | |
| PANDEY | Encapsulation of Probiotic Organisms Isolated from Fermented Food (Koozh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |